What the success rate actually means

Around 70–85% of patients in published studies achieve a good or excellent outcome from ChondroFiller injection — a figure that comes with both genuine clinical meaning and important context.

The clearest anchor for that range is Mazek 2021, a prospective cohort that followed 26 hip patients for up to 60 months after treatment of acetabular cartilage lesions greater than 2 cm². Of the 21 patients evaluable at final follow-up, 17 (81%) met the threshold for a good or excellent result. Across knee and small-joint studies, comparable proportions emerge — consistently, independently, and at multi-year timepoints.

'Good or excellent' in these trials is not a patient satisfaction score. It means meaningful improvement on validated functional measures: the IKDC scale in the knee, the Harris Hip Score in the hip, and the Lysholm score across joint types. These are the same instruments used to benchmark surgical cartilage repair procedures, which allows a degree of cross-study comparison.

Because ChondroFiller is delivered as an ultrasound-guided outpatient injection — no general anaesthetic, no theatre admission — patients weigh this efficacy picture against a substantially lower procedural burden than cartilage surgery. That context matters when interpreting what a 70–85% success rate is worth. The studies behind it are prospective and their follow-up is real, though cohort sizes have been modest; the depth of that evidence question is explored later in this article.

What the clinical studies show

The evidence spans three joints and four published datasets — a narrow base by large-trial standards, but notable for its consistency across anatomically distinct contexts.

Knee

Two knee studies bracket the dataset. Simeonov 2024 followed 17 patients (mean age 31 years) through 12 months after ChondroFiller injection for focal chondral lesions, measuring Lysholm and IKDC scores at 3, 6, and 12 months. Both scores improved significantly at every timepoint (p<0.05). There was no statistically significant difference between the 6- and 12-month readings, indicating that functional gains plateau around six months rather than continuing to accumulate.

The 2016 multicentre RCT — 13 patients in the ChondroFiller arm, 10 in the microfracture arm — remains the only randomised evidence in the literature. IKDC scores in the ChondroFiller group reached statistical significance at 3, 6, and 12 months (p<0.05); MRI confirmed immediate defect fill and progressive cartilage maturation; zero adverse events were recorded. The microfracture arm was lost to dropout, which prevented any formal cross-arm conclusion, though the ChondroFiller group's within-arm trajectory was clear.

Hip

Mazek 2021, discussed in the previous section, provides the longest follow-up in the literature — up to 60 months. The durability finding is its most clinically useful contribution: that early functional improvement is maintained rather than eroded at five years.

Wrist

A 2025 study applied ChondroFiller to intra-articular distal radius cartilage damage in 25 patients. Eight underwent second-look arthroscopy; treated joints showed significantly better cartilage quality than matched controls on both the Outerbridge scale (median 1.5 vs 3; p=0.006) and ICRS grading (grade 1 vs 3; p=0.002).

ChondroFiller is an acellular collagen scaffold that polymerises in situ and recruits the body's own stem cells and progenitor cells into the defect. The observation that this mechanism produces consistent functional gains across the knee, hip, and wrist — joints under very different mechanical demands — reflects what that underlying biology would predict, even if each individual cohort remains small.

How improvement is measured

Three validated scales translate what patients experience into numbers that clinicians and researchers can compare across studies.

The IKDC (International Knee Documentation Committee) score runs from 0 to 100, where 100 represents no symptoms and full function. A gain of approximately 30 points — the figure consistently seen in knee cohorts at 12–36 months — moves most patients from a level associated with pain-limited walking to one compatible with light sport and sustained daily activity. Thirty points is also widely regarded as the minimal threshold for a clinically meaningful improvement on this scale, so the ChondroFiller injection data clear that bar, not merely approach it.

The Harris Hip Score follows the same 0–100 logic: higher is better, 90–100 indicates no significant limitation. A mean gain of approximately 33 points in hip cohorts brings most treated patients from moderate limitation — restricted walking distance, difficulty with stairs, rest pain — into the good-to-excellent range.

MOCART is an MRI-based score, also out of 100, that assesses how completely a cartilage defect has filled and how well the repair tissue has integrated with surrounding cartilage. Scores between 70 and 87 in treated knees indicate that the defect is largely filled and structurally continuous on imaging.

The clinical significance of that last point is that structural and functional improvement align on two independent lines of evidence: what the patient reports and what the scan shows. When both move in the same direction, it provides stronger grounds for confidence than either measure alone.

Who responds well and who doesn't

The evidence points toward a responder profile built around lesion characteristics rather than joint type alone. Focal, contained chondral defects — typically under 2–6 cm² — in patients with Outerbridge or ICRS grade II–III damage and largely intact surrounding cartilage are where published cohorts consistently report good and excellent outcomes. Both Mazek 2021's hip data and the Simeonov 2024 knee cohort enrolled patients fitting this description; the 2025 wrist study extended the same profile to small joints.

Poor responders are equally consistent across studies. Patients with advanced osteoarthritis — Tönnis grade 2–3 in the hip or Kellgren-Lawrence grade III–IV in the knee — appear in the failure cohort across all published series. Diffuse or degenerative joint disease falls outside the biological premise of the treatment: a scaffold designed to recruit progenitor cells into a focal defect cannot restore cartilage that has degraded across a broad area.

Two additional factors shape outcome beyond lesion grade. A 2024 in-vitro biomechanics study found that ChondroFiller did not protect opposing cartilage surfaces under cyclic loading in the early post-treatment period, a consequence of the scaffold requiring time to stabilise before it can bear load. This makes weight-bearing restrictions after the procedure mechanically significant rather than administrative caution — patients who load the joint too early risk disrupting scaffold integration before stable defect fill is achieved. Separately, the acellular scaffold depends on the patient's own progenitor cell population to populate the matrix; systemic factors affecting stem cell availability — including age and general health — are clinically relevant, though no published trial has yet defined a quantitative threshold.

How long results last and what happens if they don't

For most patients who respond well, the benefit from a single ChondroFiller injection appears durable rather than short-lived. Published cohorts report sustained symptom relief — reduced pain, improved function — for up to three years, and the Mazek 2021 hip cohort extends meaningful follow-up to five years, with 81% of evaluable patients maintaining good or excellent outcomes at that point.

Reoperation rates across published series fall in the 3–8% range. That figure gains context when set against microfracture, the older marrow-stimulation technique it most closely displaces: microfracture produces fibrocartilage that tends to break down between two and three years post-procedure, and the subchondral bone disruption it causes can limit which repair options remain available afterwards.

ChondroFiller injection does not disturb the subchondral bone plate. This is clinically significant for patients who do not achieve full benefit: the option set — AMIC, MACI, OATS, or osteochondral allograft — remains intact. The injectable pathway closes no downstream doors.

One honest caveat on long-term durability applies to all scaffold-based repair: ChondroFiller generates fibrocartilage repair tissue rather than native hyaline cartilage. Fibrocartilage is mechanically adequate and clinically meaningful, but it is not structurally identical to the original tissue, and durability beyond five years has not yet been established in the peer-reviewed record. Patients who have read widely will encounter this distinction; it is worth raising at consultation rather than discovering later.

What the evidence doesn't yet answer

Three gaps define the limits of what the current evidence base can confidently claim.

The most consequential is the absence of any head-to-head randomised trial comparing ChondroFiller injection to ACI or OATS — the surgical benchmarks for focal cartilage repair in larger defects. Without it, the question of where ChondroFiller injection sits relative to established surgical alternatives remains open. The only published RCT (2016, n=23) aimed to compare ChondroFiller with microfracture; the microfracture arm lost too many patients to yield any cross-arm conclusion, leaving its comparative ambition unfulfilled.

Regulatory geography adds a second layer. ChondroFiller is CE-marked and established in UK and European clinical practice, but does not hold FDA approval. Patients researching through US-based sources may encounter the treatment in a different regulatory frame — context worth holding when weighing what those sources report.

The figures that have appeared throughout this article — the 70–85% success range, the approximately +30 IKDC gain — are best read as consistent findings from small prospective cohorts rather than large-trial-established certainties. Most published studies enrolled fewer than 30 patients, which places meaningful uncertainty bands around every effect-size estimate.

What those cohorts do establish is direction: meaningful benefit in appropriately selected patients, replicated across the knee, hip, and wrist, with follow-up extending to five years in the Mazek 2021 hip series. Consistent direction across anatomically distinct joints and multiple time horizons is itself a clinically meaningful signal, even before large multi-centre trials arrive to quantify it more precisely. ChondroFiller injection is available in the UK at the London Cartilage Clinic on Harley Street (londoncartilage.com), where a clinical assessment translates that population-level evidence into individual suitability — something the literature, small-cohort as it remains, cannot do on any patient's behalf.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
4. [4] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing for focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z